Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight

NCT07400588 is registered in ClinicalTrials.gov with Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics as lead sponsor.

NCT NCT07400588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07400588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety and Tolerability of Aleniglipron in Adult Participants With Type 2 Diabetes Mellitus Living With Obesity or Overweight
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 1, 2025
Completion date
September 30, 2026
Enrollment
58 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

obese, obesity, obesity type 2 diabetes mellitus, weight loss